Investing Profile

Johannes Zanzinger

InvestorVC
Investor @ BI Venture Fund at Boehringer Ingelheim
Photo of Johannes Zanzinger, Investor at Boehringer Ingelheim Venture Fund

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Pfizer Network
46 CONNECTIONS
Boehringer Ingelheim Network
13 CONNECTIONS
Boehringer Ingelheim Network
13 CONNECTIONS
Boehringer Ingelheim Network
13 CONNECTIONS
Boehringer Ingelheim Network
13 CONNECTIONS
cb
$3.3M - $17.0M
$8.5M
3
CompanyStageDateRound SizeTotal Raised
DiogenX
Series AMay 2023$37M
SeedJun 2020$5M
$42M
Co-investors: Katie Ellias (T1D Fund)
Centauri Therapeutics
Series AFeb 2022$33M
$33M
Co-investors: Sebastian Kreuz (Boehringer Ingelheim Venture Fund)
Member Board Of Directors Centauri Therapeutics LimitedPresent
Member Board Of Directors Metabomed Ltd.Present
Member Board Of Directors DiogenXPresent
Member Board Of Directors HepaRegeniX GmbHPresent
Member Board Of Directors EyevensysPresent
Member Board of Directors AgomabPresent
Investor @ BI Venture Fund Boehringer IngelheimPresent
Professor (apl) of Physiology University of UlmPresent
Global Head, Business Development & Licensing CardioMetabolic Diseases Boehringer IngelheimPresent
Head, Licensing Metabolic Diseases Boehringer IngelheimPresent
Senior Principal Scientist, R&D Coordination Boehringer IngelheimPresent
Senior Principle Scientist PfizerPresent
Associate Professor of Physiology University of HeidelbergPresent
Assistant Professor of Physiology FMF Albert Ludwigs University of Freiburg, GermanyPresent
Universität Hohenheim Dr AnPhysiology, Biology, Animal Sciences